Literature DB >> 15072186

Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia.

Takao Kimizuka1, Yutaka Ozaki, Yukiharu Sumi.   

Abstract

A 45-year-old male was admitted with difficulty in walking due to leg pain. At the time of the first visit, a reduced serum phosphorus concentration and an increased serum alkaline phosphatase concentration of unknown etiology were observed. Either a whole body bone scintigraphy or CT of the neck, chest and abdominal region did not reveal any underlying disease. However both the whole body 201Tl scintigraphy and 99mTc MIBI SPECT showed accumulation in the right knee region, and a small tumor was detected by MRI examination. After a diagnosis of oncogenic osteomalacia due to this tumor was determined the tumor was surgically removed, and turned out to be a hemangiopericytoma. By removal of the tumor, either the symptoms or the laboratory data were improved significantly. In this case, both 201Tl scintigraphy and 99mTc scintigraphy MIBI were useful in identifying the location of the tumor which caused oncogenic osteomalacia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072186     DOI: 10.1007/bf02985616

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  12 in total

1.  Biodegradable optode-based nanosensors for in vivo monitoring.

Authors:  Mary K Balaconis; Heather A Clark
Journal:  Anal Chem       Date:  2012-06-22       Impact factor: 6.986

2.  Tumor-Induced Osteomalacia.

Authors:  Rajiv Kumar; Andrew L Folpe; Brian P Mullan
Journal:  Transl Endocrinol Metab       Date:  2015

Review 3.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

4.  Tumor-induced osteomalacia.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

5.  Oncogenic osteomalacia: A reversible metabolic bone disorder.

Authors:  Dinesh Kumar Dhanwal
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

6.  Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.

Authors:  Deepa Singh; Aditi Chopra; Mudalsha Ravina; Srikant Kongara; Eesh Bhatia; Narvesh Kumar; Sushil Gupta; Subhash Yadav; Preeti Dabadghao; Rajnikant Yadav; Veeresh Dube; Utham Kumar; Manish Dixit; Sanjay Gambhir
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

7.  [Metabolic bone diseases].

Authors:  F Jakob
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

8.  Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

Authors:  William H Chong; Panagiota Andreopoulou; Clara C Chen; James Reynolds; Lori Guthrie; Marilyn Kelly; Rachel I Gafni; Nisan Bhattacharyya; Alison M Boyce; Diala El-Maouche; Diana Ovejero Crespo; Richard Sherry; Richard Chang; Felasfa M Wodajo; Gad B Kletter; Andrew Dwyer; Michael T Collins
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

9.  Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level.

Authors:  Ambika Amblee; Juanito Uy; Carmencita Senseng; Peter Hart
Journal:  Clin Kidney J       Date:  2014-02-25

10.  Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.

Authors:  Kathryn Dahir; María Belén Zanchetta; Irinel Stanciu; Cemre Robinson; Janet Y Lee; Ruban Dhaliwal; Julia Charles; Roberto Civitelli; Mary Scott Roberts; Stan Krolczyk; Thomas Weber
Journal:  J Endocr Soc       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.